	US 12,264,190 B2
	Compositions and methods of treating cancer with chimeric antigen receptors
Gordon Moody, Gaithersburg, MD (US); Maria Letizia Giardino Torchia, Gaithersburg, MD (US); Michael Glen Overstreet, Gaithersburg, MD (US); and Ryan Gilbreth, Gaithersburg, MD (US)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Sodertalje (SE)
Filed on Apr. 22, 2021, as Appl. No. 17/237,498.
Claims priority of provisional application 63/014,831, filed on Apr. 24, 2020.
Prior Publication US 2021/0332105 A1, Oct. 28, 2021
Int. Cl. C07K 14/725 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/71 (2013.01) [A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/464474 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 14/7151 (2013.01); C07K 14/7153 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/283 (2013.01); C07K 16/2836 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/303 (2013.01); C07K 16/3092 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); A61K 2239/21 (2023.05); A61K 2239/53 (2023.05); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)]

24 Claims

1. An isolated nucleic acid sequence encoding

a) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen; and

b) an armoring molecule, wherein the armoring molecule comprises a TGF-β receptor type 2 dominant-negative (TGFβRIIDN), wherein the TGFβRIIDN comprises a wild-type TGF-β receptor type 2 truncated at residue 194, and

wherein the antigen-binding domain is a single chain variable fragment (scFv) comprising the nucleic acid sequence of SEQ ID NO: 33.